1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2014

Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2014

  • April 2014
  • -
  • Global Markets Direct
  • -
  • 41 pages

Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2014’, provides an overview of the Athlete's Foot (Tinea Pedis)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Athlete's Foot (Tinea Pedis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Athlete's Foot (Tinea Pedis) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Athlete's Foot (Tinea Pedis)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Athlete's Foot (Tinea Pedis) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Athlete's Foot (Tinea Pedis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Athlete's Foot (Tinea Pedis) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Athlete's Foot (Tinea Pedis)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Athlete's Foot (Tinea Pedis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Athlete's Foot (Tinea Pedis) Overview 6
Therapeutics Development 7
Pipeline Products for Athlete's Foot (Tinea Pedis) - Overview 7
Pipeline Products for Athlete's Foot (Tinea Pedis) - Comparative Analysis 8
Athlete's Foot (Tinea Pedis) - Therapeutics under Development by Companies 9
Athlete's Foot (Tinea Pedis) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Athlete's Foot (Tinea Pedis) - Products under Development by Companies 13
Athlete's Foot (Tinea Pedis) - Companies Involved in Therapeutics Development 14
Actavis plc 14
Helix BioMedix, Inc. 15
Anacor Pharmaceuticals, Inc. 16
Viamet Pharmaceuticals, Inc. 17
Athlete's Foot (Tinea Pedis) - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
albaconazole - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
VT-1161 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
AN-2718 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
HB-1275 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
silver dihydrogen citrate - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Athlete's Foot (Tinea Pedis) - Recent Pipeline Updates 34
Athlete's Foot (Tinea Pedis) - Dormant Projects 36
Athlete's Foot (Tinea Pedis) - Product Development Milestones 37
Featured News and Press Releases 37
Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161 37
Nov 15, 2013: Valeant Pharmaceuticals Announces U.S. Approval Of Luzu Cream, 1% 38
Sep 12, 2012: Topica Pharma Presents Findings From Phase I/IIa Trial Of Luliconazole Solution In Onychomycosis At ICAAC 2012 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables

Number of Products under Development for Athlete's Foot (Tinea Pedis), H1 2014 7
Number of Products under Development for Athlete's Foot (Tinea Pedis) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Athlete's Foot (Tinea Pedis) - Pipeline by Actavis plc, H1 2014 14
Athlete's Foot (Tinea Pedis) - Pipeline by Helix BioMedix, Inc., H1 2014 15
Athlete's Foot (Tinea Pedis) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 16
Athlete's Foot (Tinea Pedis) - Pipeline by Viamet Pharmaceuticals, Inc., H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Athlete's Foot (Tinea Pedis) Therapeutics - Recent Pipeline Updates, H1 2014 34
Athlete's Foot (Tinea Pedis) - Dormant Projects, H1 2014 36

List of Figures

Number of Products under Development for Athlete's Foot (Tinea Pedis), H1 2014 7
Number of Products under Development for Athlete's Foot (Tinea Pedis) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Dermatophytic Onychomycosis- Market Insights, Epidemiology and Market Forecast-2023

Dermatophytic Onychomycosis- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Dermatophytic Onychomycosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Antifungal Drugs Market Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis) And Segment Forecasts, 2014 - 2025

Antifungal Drugs Market Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis) And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • November 2016
  • by Grand View Research

The global antifungal drugs market was valued at USD 10.7 billion in 2015 and is expected to reach a value of USD 12.6 billion by 2025. The increasing incidence of fungal infections worldwide is the key ...

Global Antifungal Drugs Market Analysis & Trends - Industry Forecast to 2025

Global Antifungal Drugs Market Analysis & Trends - Industry Forecast to 2025

  • $ 4200
  • Industry report
  • January 2017
  • by Accuray Research LLP

The Global Antifungal Drugs Market is poised to grow at a CAGR of around 1.8% over the next decade to reach approximately $12.8 billion by 2025. Some of the prominent trends that the market is witnessing ...


Download Unlimited Documents from Trusted Public Sources

The future of the Pain Relief Industry in the UK

  • February 2017
    5 pages
  • Pain Relief  

  • United Kingdom  

View report >

Antiseptics Markets

  • December 2016
    58 pages
  • Antiseptics  

    Anti-Infective  

View report >

Spinach Industry in the US

  • December 2016
    9 pages
  • Spinach  

    Food  

    Mineral Supplem...  

  • United States  

View report >

Otc Industry In India

9 months ago

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.